Axela Receives Key Patent on Light Diffraction Based Assays and Opens US Facility.Patent Defines Leading Position in Development of Novel Protein Research and Diagnostic Tools TORONTO -- Axela Inc., a recognized innovator in protein interaction technology, today announced it has been issued patent number 7,314,749, "Method and apparatus for assay based on light diffraction" by the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property . This core patent augments over 150 other patents and applications which define the company as the leading provider of novel protein research and diagnostic tools based on diffractive dif·fract intr. & tr.v. dif·fract·ed, dif·fract·ing, dif·fracts To undergo or cause to undergo diffraction. [Back-formation from diffraction. optic measurements. Additionally the company announced it has changed its name from Axela Biosensors Inc. to Axela Inc. to reflect the broad range of applications and markets served by its technology beyond traditional biosensing. Axela has established operations in a GMP/GLP facility in Foster City, California
An assay that quantifies antigen or antibody by immunochemical means. The antigen can be a relatively simple substance such as a drug, or a complex one such as a protein or a virus. kits for the dotLab[TM] System. "The issuance of this patent further reinforces the strong intellectual property position Axela has established in the use of diffractive optics to significantly improve the performance of immunoassays in research and diagnostic applications," commented Rocky Ganske, Axela CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "Initial product offerings available through our partner VWR International VWR International is a global leader in the distribution of research laboratory products, with over 1,200,000 items to more than 250,000 customers in North America and Europe. The U.S. division is headquartered in West Chester, Pennsylvania. are focused on accelerating the study of biomolecular interactions, optimizing protein expression and the rapid development of quantitative immunoassays for the research markets. Axela and its collaborators have already demonstrated the benefits of real-time measurements that extend the dynamic range of multiplex analysis and access unique diagnostic targets. This is reflected in our recent name change and the expansion of US operations to commercialize proprietary content and panels." About Axela Inc. Axela has developed a proprietary technology for real time protein detection, characterization A rather long and fancy word for analyzing a system or process and measuring its "characteristics." For example, a Web characterization would yield the number of current sites on the Web, types of sites, annual growth, etc. and monitoring directly in biological samples. The company's products provide life science and clinical researchers simple tools and reagents to study interactions, expand the utility of traditional immunoassays and access novel categories of diagnostic markers. Participating in the research market provides unique access to novel discoveries that form the basis of a growing content pipeline for future multiplex diagnostic offerings. Axela is a privately-held company with operations in Toronto and California whose major investor is VenGrowth Private Equity Partners Inc., one of Canada's premier private equity managers. For more information, please visit www.axela.com or contact: (c) 2008 Axela Inc. All rights reserved. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion